You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南京醫藥(600713.SH)擬與德軒堂醫藥及錦康富益共設合資公司 專營血液製品業務
格隆匯 06-29 15:39

格隆匯 6 月 29日丨南京醫藥(600713.SH)公佈,公司擬與江蘇德軒堂醫藥(集團)有限公司(“德軒堂醫藥”)、南京錦康富益企業諮詢管理合夥企業(有限合夥)(“錦康富益”)共同以現金方式出資3000萬元(人民幣,下同)設立南京醫藥江蘇德軒堂生物製品有限公司(以工商實際核准名稱為準,“合資公司”)。其中公司出資1530萬元,佔合資公司註冊資本的51%;德軒堂醫藥出資1050萬元,佔合資公司註冊資本的35%;錦康富益出資420萬元,佔合資公司註冊資本的14%。

德軒堂醫藥是一家專注於血液製品、新特藥銷售的醫藥企業,具有豐富且成功的全系列血液製品江蘇地區總代理的市場開拓與管理經驗,目前在江蘇血液製品市場佔有領先、重要地位。

錦康富益合夥人主要系德軒堂醫藥委派至合資公司的原血液製品業務核心團隊成員,並作為整合合資公司業務供應鏈資源平台。

南京醫藥與德軒堂醫藥、錦康富益擬簽署《關於南京醫藥江蘇德軒堂生物製品有限公司(籌)之合資經營協議》,合作意義及目標為雙方在國家醫療衞生體制改革的框架下,結合各自優勢合資成立生物製品公司,專營血液製品,先立足江蘇,再輻射全國,力爭在三年時間內,發展成為江蘇省內規模及醫療機構覆蓋範圍均領先的血液製品專營企業,成為江蘇市場血液製品細分領域領導者。

此次公司與德軒堂醫藥合資成立定位於雙方在江蘇區域市場的血液製品資源整合平台和經銷配送平台,將有利於公司把握血液製品市場發展機遇,在主業量質並舉發展的同時,協同行業優勢資源在江蘇省內血液製品細分行業領域做優做強做大,並與公司主要業務區域形成協同聯動效應。此次投資交易預計不會對公司2020年主營業務產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account